Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben Sprangers

Showing results (1-10 of 182) with videos related to

Pageof 19
Sort By:
Clinical Kidney Journal|February 13, 2019
Pembrolizumab-related renal toxicities: diagnosis first, treatment laterBen Sprangers
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 3, 2018
Aetiology and management of acute kidney injury in multiple myelomaBen Sprangers
Kidney360|April 4, 2022
Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: PROMark Eijgelsheim, Ben Sprangers
NDT Plus|June 29, 2017
IgG4-related disease should be considered in cases of hypocomplementemic immune-complex tubulointerstitial nephritisBen Sprangers, Kathleen Claes
Transplantation|June 18, 2010
Pediatric organ allocation: matching tissue and needsBen Sprangers, Yves Vanrenterghem
Clinical Kidney Journal|September 26, 2022
'Prevention is better than cure': warning for comedications in patients receiving immune checkpoint inhibitors to avoid acute kidney injuryJulie Belliere, Ben Sprangers
Clinical Journal of the American Society of Nephrology : CJASN|October 17, 2014
The hype cycle for soluble urokinase receptor in FSGS: passing the trough of disillusionment?Björn Meijers, Ben Sprangers
Transplantation|June 16, 2010
Steroid avoidance or withdrawal after kidney transplantation: a balancing actBen Sprangers, Yves Vanrenterghem
Clinical Kidney Journal|September 8, 2020
The growing pains of ifosfamideBen Sprangers, Sebastian Lapman
Clinical Kidney Journal|April 3, 2023
Pseudo-AKI associated with targeted anti-cancer agents-the truth is in the eye of the filtration markerThomas Vanhoutte, Ben Sprangers
Pageof 19

Showing results (1-10 of 182) with videos related to

Sort By:
Pageof 19
Clinical Kidney Journal|February 13, 2019
Pembrolizumab-related renal toxicities: diagnosis first, treatment laterBen Sprangers
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 3, 2018
Aetiology and management of acute kidney injury in multiple myelomaBen Sprangers
Kidney360|April 4, 2022
Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: PROMark Eijgelsheim, Ben Sprangers
NDT Plus|June 29, 2017
IgG4-related disease should be considered in cases of hypocomplementemic immune-complex tubulointerstitial nephritisBen Sprangers, Kathleen Claes
Transplantation|June 18, 2010
Pediatric organ allocation: matching tissue and needsBen Sprangers, Yves Vanrenterghem
Clinical Kidney Journal|September 26, 2022
'Prevention is better than cure': warning for comedications in patients receiving immune checkpoint inhibitors to avoid acute kidney injuryJulie Belliere, Ben Sprangers
Clinical Journal of the American Society of Nephrology : CJASN|October 17, 2014
The hype cycle for soluble urokinase receptor in FSGS: passing the trough of disillusionment?Björn Meijers, Ben Sprangers
Transplantation|June 16, 2010
Steroid avoidance or withdrawal after kidney transplantation: a balancing actBen Sprangers, Yves Vanrenterghem
Clinical Kidney Journal|September 8, 2020
The growing pains of ifosfamideBen Sprangers, Sebastian Lapman
Clinical Kidney Journal|April 3, 2023
Pseudo-AKI associated with targeted anti-cancer agents-the truth is in the eye of the filtration markerThomas Vanhoutte, Ben Sprangers
Pageof 19